New CAR T-cell therapy for solid tumours

This abstract, presented at ESMO 2022, reports on the first in-human data for claudin 6 (CLDN6)-positive solid tumors treated with BNT211, which contains two therapeutic components: CLDN6-targeted CAR T cells and a CLDN6-encoding RNA vaccine that was designed to amplify and transfer the CAR T cells. Patients with ovarian and testicular cancers received BNT211, and seven of 21 patients had partial response and eight had stable disease. Dose-limiting toxicity and progressive disease are discussed in the abstract.